119 related articles for article (PubMed ID: 25669612)
1. Genotype-based dosage of acenocoumarol in highly-sensitive geriatric patients.
Lozano R; Franco ME; López L; Moneva JJ; Carrasco V; Pérez-Layo MA
Int J Clin Pharmacol Ther; 2015 Mar; 53(3):206-10. PubMed ID: 25669612
[TBL] [Abstract][Full Text] [Related]
2. Effect of CYP2C9 and VKORC1 genetic polymorphisms on mean daily maintenance dose of acenocoumarol in South Indian patients.
Krishna Kumar D; Madhan S; Balachander J; Sai Chandran BV; Thamijarassy B; Adithan C
Thromb Res; 2013 Apr; 131(4):363-7. PubMed ID: 23473641
[TBL] [Abstract][Full Text] [Related]
3. Genotype-guided therapy improves initial acenocoumarol dosing. Results from a prospective randomised study.
Cerezo-Manchado JJ; Roldán V; Corral J; Rosafalco M; Antón AI; Padilla J; Vicente V; González-Conejero R
Thromb Haemost; 2016 Jan; 115(1):117-25. PubMed ID: 26538428
[TBL] [Abstract][Full Text] [Related]
4. CYP2C9 and VKORC1 in therapeutic dosing and safety of acenocoumarol treatment: implication for clinical practice in Hungary.
Varnai R; Sipeky C; Nagy L; Balogh S; Melegh B
Environ Toxicol Pharmacol; 2017 Dec; 56():282-289. PubMed ID: 29055218
[TBL] [Abstract][Full Text] [Related]
5. Creating a genotype-based dosing algorithm for acenocoumarol steady dose.
Cerezo-Manchado JJ; Rosafalco M; Antón AI; Pérez-Andreu V; Garcia-Barberá N; Martinez AB; Corral J; Vicente V; González-Conejero R; Roldán V
Thromb Haemost; 2013 Jan; 109(1):146-53. PubMed ID: 23196355
[TBL] [Abstract][Full Text] [Related]
6. Influence of VKORC1 and CYP2C9 Polymorphisms on Daily Acenocoumarol Dose Requirement in South Indian Patients With Mechanical Heart Valves.
Kalpana SR; Bharath G; Manjunath CN; Christopher R
Clin Appl Thromb Hemost; 2017 Oct; 23(7):876-882. PubMed ID: 27335128
[TBL] [Abstract][Full Text] [Related]
7. Effect of different genetics variants: CYP2C9*2, CYP2C9*3 of cytochrome P-450 CYP2C9 and 1639G>A of the VKORC1 gene; On acenocoumarol requirement in Moroccan patients.
Smires FZ; Habbal R; Moreau C; Assaidi A; Loriot MA; Nadifi S
Pathol Biol (Paris); 2013 Jun; 61(3):88-92. PubMed ID: 23201087
[TBL] [Abstract][Full Text] [Related]
8. Dosing algorithms for vitamin K antagonists across VKORC1 and CYP2C9 genotypes.
Baranova EV; Verhoef TI; Ragia G; le Cessie S; Asselbergs FW; de Boer A; Manolopoulos VG; Maitland-van der Zee AH;
J Thromb Haemost; 2017 Mar; 15(3):465-472. PubMed ID: 28063245
[TBL] [Abstract][Full Text] [Related]
9. Effect of CYP2C9, VKORC1, CYP4F2, and GGCX gene variants and patient characteristics on acenocoumarol maintenance dose: Proposal for a dosing algorithm for Moroccan patients.
Elkhazraji A; Bouaiti EA; Boulahyaoui H; Nahmtchougli CP; Zahid H; Bensaid M; Ibrahimi A; Messaoudi N
Drug Discov Ther; 2018; 12(2):68-76. PubMed ID: 29760340
[TBL] [Abstract][Full Text] [Related]
10. VKORC1 and CYP2C9 allelic variants influence acenocoumarol dose requirements in Greek patients.
Markatos CN; Grouzi E; Politou M; Gialeraki A; Merkouri E; Panagou I; Spiliotopoulou I; Travlou A
Pharmacogenomics; 2008 Nov; 9(11):1631-8. PubMed ID: 19018719
[TBL] [Abstract][Full Text] [Related]
11. Long-term anticoagulant effects of the CYP2C9 and VKORC1 genotypes in acenocoumarol users.
Verhoef TI; Redekop WK; Buikema MM; Schalekamp T; Van Der Meer FJ; Le Cessie S; Wessels JA; Van Schie RM; De Boer A; Teichert M; Visser LE; Maitland-Van Der Zee AH;
J Thromb Haemost; 2012 Apr; 10(4):606-14. PubMed ID: 22252093
[TBL] [Abstract][Full Text] [Related]
12. [Effect of VKORC1 and CYP2C9 variants on dosage of oral anticoagulants in Chilean individuals].
Benavides F; Grossman N; Poggi H; Nieto E; Bertrán A; Araos D; Vásquez M; Ibarra I; Cáceres F; Espinoza K; Lagos M; Repetto M G
Rev Med Chil; 2015 Nov; 143(11):1369-76. PubMed ID: 26757860
[TBL] [Abstract][Full Text] [Related]
13. Pharmacogenetics role in the safety of acenocoumarol therapy.
Jiménez-Varo E; Cañadas-Garre M; Henriques CI; Pinheiro AM; Gutiérrez-Pimentel MJ; Calleja-Hernández MÁ
Thromb Haemost; 2014 Sep; 112(3):522-36. PubMed ID: 24919870
[TBL] [Abstract][Full Text] [Related]
14. Pharmacogenetic-guided dosing of coumarin anticoagulants: algorithms for warfarin, acenocoumarol and phenprocoumon.
Verhoef TI; Redekop WK; Daly AK; van Schie RM; de Boer A; Maitland-van der Zee AH
Br J Clin Pharmacol; 2014 Apr; 77(4):626-41. PubMed ID: 23919835
[TBL] [Abstract][Full Text] [Related]
15. Influence of genetic and non-genetic factors on acenocoumarol maintenance dose requirement in a Tunisian population.
Ajmi M; Omezzine A; Achour S; Amor D; Hamdouni H; Ismaïl FBF; Rejeb NB; Kechrid CL; Boughzela E; Bouslama A
Eur J Clin Pharmacol; 2018 Jun; 74(6):711-722. PubMed ID: 29479633
[TBL] [Abstract][Full Text] [Related]
16. Pharmacogenetics of acenocoumarol: CYP2C9 *2 and VKORC1 c.-1639G>A, 497C>G, 1173C>T, and 3730G>A variants influence drug dose in anticoagulated patients.
Verde Z; Santiago C; Valle B; Fernández-Santander A; Bandrés F; Calvo E; Ruiz JR; Lucía A; Gallego FG
Thromb Haemost; 2009 Mar; 101(3):591-3. PubMed ID: 19277427
[No Abstract] [Full Text] [Related]
17. Impact of genetic and clinical factors on dose requirements and quality of anticoagulation therapy in Polish patients receiving acenocoumarol: dosing calculation algorithm.
Wolkanin-Bartnik J; Pogorzelska H; Szperl M; Bartnik A; Koziarek J; Bilinska ZT
Pharmacogenet Genomics; 2013 Nov; 23(11):611-8. PubMed ID: 24108193
[TBL] [Abstract][Full Text] [Related]
18. Effect of VKORC1, CYP2C9 and CYP4F2 genetic variants in early outcomes during acenocoumarol treatment.
Cerezo-Manchado JJ; Roldan V; Rosafalco M; Anton AI; Arroyo AB; Garcia-Barbera N; Martínez AB; Padilla J; Corral J; Vicente V; Gonzalez-Conejero R
Pharmacogenomics; 2014 May; 15(7):987-96. PubMed ID: 24956252
[TBL] [Abstract][Full Text] [Related]
19. Role of CYP4F2, CYP2C19, and CYP1A2 polymorphisms on acenocoumarol pharmacogenomic algorithm accuracy improvement in the Greek population: need for sub-phenotype analysis.
Ragia G; Karantza IM; Kelli-Kota E; Kolovou V; Kolovou G; Konstantinides S; Maltezos E; Tavridou A; Tziakas D; Maitland-van der Zee AH; Manolopoulos VG
Drug Metab Pers Ther; 2017 Dec; 32(4):183-190. PubMed ID: 29252193
[TBL] [Abstract][Full Text] [Related]
20. Effect of CYP2C9-VKORC1 interaction on warfarin stable dosage and its predictive algorithm.
Li X; Liu R; Yan H; Tang J; Yin JY; Mao XY; Yang F; Luo ZY; Tan SL; He H; Chen XP; Liu ZQ; Li Z; Zhou HH; Zhang W
J Clin Pharmacol; 2015 Mar; 55(3):251-7. PubMed ID: 25187307
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]